| Abstract: | ![]()
It is widely accepted that tumor metastasis is the dominant factor leading to cancer-related death. Tumor metastasis is mediated by cell invasion, blood circulation and lymphatic circulation. Paclitaxel, as a common anti-tumordrug and a mitotic inhibitor, promotes microtubule assembly and inhibits microtubule depolymerization. In addition, ticagrelor, an anti-platelet drug, is used to treat acute coronary syndrome. Increasing numbers of studieshave reported that platelets can facilitate tumor metastasis. Therefore, inhibiting the effects of platelets can serveas a novel therapeutic strategy for cancer. To explore the effect of anti-tumor and anti-platelet drugs on tumorprogression, we chose paclitaxel and ticagrelor. Interestingly, the results demonstrated that paclitaxel and ticagrelor could not only suppress the proliferation, migration and invasion of B16F10 and LLC cells, but they could alsoprevent tumor metastasis to the lungs. Furthermore, the inhibitory effect of paclitaxel and ticagrelor was moreapparent when both drugs were used in combination. Collectively, the current study demonstrated that the combination of paclitaxel and ticagrelor could be considered as a potential anti-tumor therapy approach. |
